EGFR and lung cancer: IL-6 was decreased in both of the erlotinib-sensitive EGFR-mutant lung cancer cell lines (HCC4006 and HCC827) and was not changed in the erlotinib-resistant EGFR-mutant lung cancer line (H1975) after erlotinib treatment.